Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production.

Hisakata Yamada, Tomomi Tsuru, Takeshi Otsuka, Masayuki Maekawa, Hiroshi Harada, Takaaki Fukuda, Hiroshi Tsukamoto, Akira Maeyama, Shigeru Yoshizawa, Ken Wada, Yasuharu Nakashima, Eisuke Shono, Seiji Yoshizawa, Hiroshi Jojima, Masakazu Kondo

Journal: Immunological medicine 2020;43(2):87-91

PMID: 31994996

Free Full Text on Atypon View on PubMed

Abstract

Abatacept may exert its clinical effect on rheumatoid arthritis (RA) by suppressing anti-cyclic citrullinated peptide (CCP) antibody production. This study was undertaken to test this hypothesis by examining the changes of disease activity of RA and anti-CCP antibody levels over time after starting abatacept. Sixty Japanese RA patients who started abatacept were included in this multicenter, prospective observational study. Simple Disease Activity Index (SDAI) and anti-CCP antibody levels were evaluated at 12, 24, and 52 weeks. The mean SDAI score significantly decreased within 12 weeks after starting abatacept and was maintained thereafter. On the contrary, the mean anti-CCP antibody levels did not change until 52 weeks. At the individual level, there were substantial changes of anti-CCP antibody levels, but these were not correlated with the changes of disease activity at any time points. Thus, abatacept reduces the disease activity of RA independently of modulating anti-CCP antibody production.

Address: Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan.; Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.; Kondo Clinic of Rheumatology and Orthopaedic Surgery, Fukuoka, Japan.; PS Clinic, Fukuoka, Japan.; Munakata Medical Association Hospital, Fukuoka, Japan.; Maekawa Clinic of Rheumatology and Orthopedic Surgery, Fukuoka, Japan.; Morooka Orthopedic Clinic, Fukuoka, Japan.; Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan.; Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan.; Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.; National Hospital Organization Fukuoka Hospital, Fukuoka, Japan.; Wada Orthopaedic Clinic, Fukuoka, Japan.; Shono Rheumatology Clinic, Fukuoka, Japan.; Hamanomachi Hospital, Fukuoka, Japan.; Department of Orthopaedic Surgery, Fukuoka University Chikushi Hospital, Fukuoka, Japan.

DOI: 10.1080/25785826.2020.1718833

Link outs

Free resources

Full Text Sources:

https://www.tandfonline.com/doi/10.1080/25785826.2...

Medical:

https://medlineplus.gov/rheumatoidarthritis.html

MeSH Terms: Abatacept, Aged, Anti-Citrullinated Protein Antibodies, Antibody Formation, Arthritis, Rheumatoid, Female, Humans, Male, Middle Aged